Results 11 to 20 of about 31,699 (207)

A New Twist: The Combination of Sulbactam/Avibactam Enhances Sulbactam Activity against Carbapenem-Resistant Acinetobacter baumannii (CRAB) Isolates [PDF]

Antibiotics, 2021
An increasing number of untreatable infections are recorded every year. Many studies have focused their efforts on developing new β-lactamase inhibitors to treat multi-drug resistant (MDR) isolates. In the present study, sulbactam/avibactam and sulbactam/
Fernando Pasteran, Jose Cedano, Michelle Baez, Ezequiel Albornoz, Melina Rapoport, Jose Osteria, Sabrina Montaña, Casin Le, Grace Ra, Robert A. Bonomo, Marcelo E. Tolmasky, Mark Adams, Alejandra Corso, Maria Soledad Ramirez   +13 more
doaj   +2 more sources

Zidebactam restores sulbactam susceptibility against carbapenem-resistant Acinetobacter baumannii isolates [PDF]

Frontiers in Cellular and Infection Microbiology, 2022
Carbapenems are commonly used to treat infections caused by multidrug-resistant (MDR) bacteria. Unfortunately, carbapenem resistance is increasingly reported in many gram-negative bacteria, especially Acinetobacter baumannii.
Jose Cedano, Michelle Baez, Fernando Pasteran, Sabrina Daiana Montaña, Grace Ra, Venjaminne Fua, Alejandra Corso, Marcelo E. Tolmasky, Robert A. Bonomo, Robert A. Bonomo, Robert A. Bonomo, María Soledad Ramírez   +11 more
doaj   +2 more sources

Clinical Outcomes of Pandrug-Resistant Versus Carbapenem-Resistant, Colistin-Susceptible <i>Acinetobacter baumannii</i> Infections: A Retrospective Analysis of a Prospective Multicentre Cohort. [PDF]

Antibiotics (Basel)
Background: Pandrug-resistant (PDR) Acinetobacter baumannii represents a major therapeutic challenge in regions where carbapenem-resistant A. baumannii (CRAB) is endemic.
Karaiskos I, Daikos GL, Michelidou S, Mouratidou C, Gavala A, Gkoufa A, Sakagianni A, Mouloudi E, Tsigou E, Routsi C, Karakonstantis S, Stamatopoulou C, Markantonaki D, Veroniki F, Pirounaki M, Kyriakoudi A, Ampelioti S, Anastogiannis C, Koutsoukou A, Giamarellou H, Pontikis K.   +20 more
europepmc   +2 more sources

Evaluation of Fosfomycin-Sulbactam Combination Therapy against Carbapenem-Resistant Acinetobacter baumannii Isolates in a Hollow-Fibre Infection Model

Antibiotics, 2022
Static concentration in vitro studies have demonstrated that fosfomycin- or sulbactam-based combinations may be efficacious against carbapenem-resistant Acinetobacter baumannii (CRAB).
Sazlyna Mohd Sazlly Lim, Aaron Heffernan, Saiyuri Naicker, Steven Wallis, Jason A. Roberts, Fekade Bruck Sime   +5 more
doaj   +2 more sources

Impact of multisite colonization and comparative microbiological outcomes of colistin-sulbactam vs. colistin-tigecycline in CRAB hospital-acquired pneumonia: a propensity score-matched analysis. [PDF]

Front Cell Infect Microbiol
BackgroundThe optimal combination therapy for carbapenem-resistant Acinetobacter baumannii (CRAB) pneumonia remains controversial. This study aimed to compare the microbiological efficacy, clinical outcomes, and safety of colistin-sulbactam versus ...
Liao S, Shen L.
europepmc   +2 more sources

Comparing the Outcomes of Cefoperazone/Sulbactam-Based and Non-Cefoperazone/Sulbactam-Based Therapeutic Regimens in Patients with Multiresistant Acinetobacter baumannii Infections—A Meta-Analysis

Antibiotics
The addition of sulbactam restores the complete range of cefoperazone activity against bacteria and extends its spectrum of action to include the Acinetobacter species.
Chienhsiu Huang, Lichen Lin, Sufang Kuo
doaj   +2 more sources

Contribution of Acinetobacter-derived cephalosporinase-30 to sulbactam resistance in Acinetobacter baumannii [PDF]

Frontiers in Microbiology, 2015
The sulbactam resistance rate in Acinetobacter baumannii has increased worldwide. Previous reports have shown that the β-lactamase blaTEM-1 confers resistance to sulbactam in A. baumannii.
Shu-Chen eKuo, Yi-Tzu eLee, Tsai-Ling eYang Lauderdale, Wei-Cheng eHuang, Ming-Fen eChuang, Chien-Pei eChen, Shey-Chiang eSu, Kuan-Rong eLee, Te-Li eChen, Te-Li eChen   +9 more
doaj   +3 more sources

The combination effect of meropenem/sulbactam/polymyxin-B on the pharmacodynamic parameters for mutant selection windows against carbapenem-resistant Acinetobacter baumannii

Frontiers in Microbiology, 2022
The objective of this study was to evaluate whether combinations of sulbactam, meropenem, and polymyxin-B could reduce or close the gap of mutant selection window (MSW) of individual antibiotics against Acinetobacter baumannii harboring OXA-23.
Jiayuan Zhang, Shuo Diao, Yanfei Liu, Hongxiang Wang, Yuwei Liu, Shixing Zhu, Kun Feng, Xiaoqian Tang, Charles Oo, Peijuan Zhu, Zhihua Lv, Zhihua Lv, Mingming Yu, Mingming Yu, Sherwin K. B. Sy, Yuanqi Zhu   +15 more
doaj   +1 more source

Cefiderocol and Sulbactam-Durlobactam against Carbapenem-Resistant Acinetobacter baumannii [PDF]

, 2023
Infections caused by carbapenem-resistant Acinetobacter baumannii (CRAB) remain a clinical challenge due to limited treatment options. Recently, cefiderocol, a novel siderophore cephalosporin, and sulbactam-durlobactam, a bactericidal β-lactam–β ...
Zarrilli R., Migliaccio A., Karruli A., Durante-Mangoni E., Pournaras S.   +4 more
core   +4 more sources

Durlobactam, a New Diazabicyclooctane β-Lactamase Inhibitor for the Treatment of Acinetobacter Infections in Combination With Sulbactam

Frontiers in Microbiology, 2021
Durlobactam is a new member of the diazabicyclooctane class of β-lactamase inhibitors with broad spectrum activity against Ambler class A, C, and D serine β-lactamases.
Adam B. Shapiro, Samir H. Moussa, Sarah M. McLeod, Thomas Durand-Réville, Alita A. Miller   +4 more
doaj   +1 more source